Adjuvants for peptide-based cancer vaccines
Cancer therapies based on T cells have shown impressive clinical benefit. In particular, immune checkpoint blockade therapies with anti-CTLA-4 and anti-PD-1/PD-L1 are causing dramatic tumor shrinkage and prolonged patient survival in a variety of cancers. However, many patients do not benefit, possi...
Saved in:
| Main Authors: | Willem W Overwijk, Hiep Khong |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2016-09-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/4/1/56.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Combined cancer immunotherapy with lipid nanoparticle delivery of oligo-based cGAS-agonistic adjuvant and peptide or mRNA vaccines
by: Shurong Zhou, et al.
Published: (2025-09-01) -
Carbohydrate-Based Adjuvants for Vaccine Production
by: S. S. Kurashova, et al.
Published: (2018-06-01) -
Lipoprotein Signal Peptide as Adjuvants: Leveraging Lipobox-Driven TLR2 Activation in Modern Vaccine Design
by: Muhammad Umar, et al.
Published: (2025-01-01) -
Development of a vaccine adjuvant based on squalene and study of its adjuvant properties
by: E. A. Volosnikova, et al.
Published: (2023-06-01) -
Toll-like receptor agonists as cancer vaccine adjuvants
by: Donghwan Jeon, et al.
Published: (2024-12-01)